A retrospective study assessing the prevalence, risk factors and demographic characteristics of immune checkpoint inhibitor-associated primary adrenal insufficiency
Latest Information Update: 01 Aug 2022
At a glance
- Drugs Ipilimumab (Primary) ; Nivolumab (Primary)
- Indications Cancer
- Focus Adverse reactions
Most Recent Events
- 01 Aug 2022 New trial record
- 23 Jul 2022 Results published in the Journal of Endocrinological Investigation